US 12,064,429 B2
Substituted 5-fluoro-1H-pyrazolopyridines and their use
Markus Follmann, Cologne (DE); Johannes-Peter Stasch, Solingen (DE); Gorden Redlich, Bochum (DE); Jens Ackerstaff, Dusseldorf (DE); Nils Griebenow, Dormagen (DE); Walter Kroh, Wuppertal (DE); Andreas Knorr, Erkrath (DE); Eva-Maria Becker, Wuppertal (DE); Frank Wunder, Wuppertal (DE); Volkhart Min-Jian Li, Velbert (DE); Elke Hartmann, Wuppertal (DE); Joachim Mittendorf, Wuppertal (DE); Karl-Heinz Schlemmer, Wuppertal (DE); Rolf Jautelat, Haan (DE); and Donald Bierer, Berlin (DE)
Assigned to Adverio Pharma GmbH, Leverkusen (DE)
Filed by Adverio Pharma GmbH, Leverkusen (DE)
Filed on Aug. 18, 2022, as Appl. No. 17/820,667.
Application 16/919,385 is a division of application No. 15/981,598, filed on May 16, 2018, granted, now 10,736,896, issued on Aug. 11, 2020.
Application 17/820,667 is a continuation of application No. 16/919,385, filed on Jul. 2, 2020, granted, now 11,439,642.
Application 15/981,598 is a continuation of application No. 15/348,545, filed on Nov. 10, 2016, granted, now 9,993,476, issued on Jun. 12, 2018.
Application 15/348,545 is a continuation of application No. 14/996,678, filed on Jan. 15, 2016, abandoned.
Application 14/996,678 is a continuation of application No. 14/552,122, filed on Nov. 24, 2014, granted, now 9,266,885, issued on Feb. 23, 2016.
Application 14/552,122 is a continuation of application No. 13/851,373, filed on Mar. 27, 2013, granted, now 8,921,377, issued on Dec. 30, 2014.
Application 13/851,373 is a continuation of application No. 13/111,856, filed on May 19, 2011, granted, now 8,420,656, issued on Apr. 16, 2013.
Claims priority of application No. 102010021637.2 (DE), filed on May 26, 2010.
Prior Publication US 2022/0409618 A1, Dec. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/506 (2006.01); A61K 45/06 (2006.01); C07C 57/145 (2006.01); C07C 309/04 (2006.01); C07C 309/05 (2006.01); C07D 471/04 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 45/06 (2013.01); C07C 57/145 (2013.01); C07C 309/04 (2013.01); C07C 309/05 (2013.01); C07D 471/04 (2013.01)] 18 Claims
 
1. A method of improving perception, concentration, learning or memory after cognitive impairments occurring in association with a situation, disease, or syndrome selected from the group consisting of mild cognitive impairment, age-associated learning and memory impairments, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after stroke, post-traumatic craniocerebral trauma, general concentration impairments, concentration impairments in children with learning and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyolateral sclerosis, Huntington's disease, demyelination, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, schizophrenia with dementia and Korsakoff's psychosis, the method comprising administering a therapeutically effective amount of a compound of formula (I-A)

OG Complex Work Unit Chemistry
or a salt thereof to a human or animal in need thereof.